Schellenberg Wittmer with Kinarus in its agreement with Perfect Holding

Kinarus, a privately owned clinical-stage biopharmaceutical company active in the development of novel treatments for patients suffering from serious viral, respiratory and ophthalmic diseases, signed a Transaction Agreement with SIX-listed Perfect Holding regarding Perfect Holding’s planned acquisition of Kinarus by way of a share exchange.

The closing of the transaction is subject to the fulfilment of specific conditions, including the approval by SIX Swiss Exchange of the listing of the new shares to be issued to the shareholders of Kinarus, and the approval of the envisaged transaction by the shareholders of both companies.

Schellenberg Wittmer advises Kinarus in this transaction. The team consists of partner Oliver Triebold (pictured), partner Marcel Jakob, associate Nicolas Kurz, trainee lawyer Laura Roth, paralegal Irisi Arifi (all corporate/m&a), partner Michael Nordin, associate Roland Wild (all tax), partner Olivier Favre, associate Fabio Elsener, associate Dominic Wälchli, Manager FlexLaw Daniel Reinger (all banking & finance), partner Lorenza Ferrari Hofer, trainee lawyer Dimitry Bölsterli (IP/life sciences).